Month: August 2025

Aug 19 2025

Uncategorized

Is ketamine the answer for chronic pain? New findings cast doubt

by Clinical Editor

No Comments

A sweeping review of 67 trials has cast doubt on the use of ketamine and similar NMDA receptor antagonists for chronic pain relief. While ketamine is frequently prescribed off-label for...

Aug 18 2025

Uncategorized

Rare Pica Case: Man, Swallows Pen, IV Tubes, and More – Medscape

by Clinical Editor

No Comments

Rare Pica Case: Man, Swallows Pen, IV Tubes, and More  Medscape

Aug 18 2025

Uncategorized

Man with schizophrenia missing in Markham – WGN-TV

by Clinical Editor

No Comments

Man with schizophrenia missing in Markham  WGN-TV

Aug 17 2025

Uncategorized

Gen Zer’s moment that led to schizophrenia diagnosis: “that’s how you know”

by Clinical Editor

No Comments

Mackenzie Salmonson, 26, told Newsweek that she speaks openly about her chronic mental health condition in hopes of breaking the stigma surrounding it.

Aug 17 2025

Uncategorized

Scientists discover eight new schizophrenia genes

by Clinical Editor

No Comments

Researchers have discovered eight new genes associated with schizophrenia, in the largest exome-sequencing study of the disorder ever conducted. The breakthrough, made by scientists at the Centre for …

Aug 16 2025

Uncategorized

Longitudinal changes in striatocortical connectivity in first-episode psychosis associated with the emergence of treatment resistance – Nature

by Clinical Editor

No Comments

Longitudinal changes in striatocortical connectivity in first-episode psychosis associated with the emergence of treatment resistance  Nature

Aug 16 2025

Uncategorized

New schizophrenia drug improves symptoms current drugs can’t touch

by Clinical Editor

No Comments

A novel drug, evenamide, quieted overactive brain circuits in an animal model of schizophrenia, improving memory, social interaction, and dopamine balance, offering hope for tackling symptoms that …

Aug 15 2025

Uncategorized

Newron randomises first subjects in Phase III programme for schizophrenia

by Clinical Editor

No Comments

“Newron randomises first subjects in Phase III programme for schizophrenia” was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

Aug 15 2025

Uncategorized

RL-007 Poised to Transform CIAS Market as First Targeted Therapy for Cognitive Deficits in Schizophrenia | DelveInsight

by Clinical Editor

No Comments

As RL-007 progresses through late-stage clinical development, it represents a significant advancement in schizophrenia treatment, potentially offering one of the first approved therapies specifically …

Aug 14 2025

Uncategorized

‘I’m lucky to be alive’: Man with schizophrenia claims abuse by Warren police during mental health crisis

by Clinical Editor

No Comments

A Detroit man says he experienced cruelty and abuse during a mental health crisis encounter with Warren police.